All In Biotech

Free tool

FAERS Monitor: Vyvgart

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761195 or its brand name (Vyvgart, Efgartigimod Alfa). Reports on generic versions are filed under their own applications.

Reports

3,968

Serious

3,661

92% of reports

Hospitalization

1,915

Death reported

379

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • myasthenia gravis785
  • myasthenia gravis crisis455
  • fatigue404
  • dyspnoea301
  • asthenia263
  • fall224
  • drug ineffective216
  • urinary tract infection214
  • muscular weakness199
  • headache192
  • death191
  • dysphagia179
  • off label use178
  • hospitalisation175
  • covid-19174

Reports by year received

View as table
YearReports
20205
20213
2022349
20231,194
20241,669
2025451
2026297

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,191 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myasthenia gravis crisisSignal4552348.02112.1738,365
myasthenia gravisSignal785570.5533.6402,561
dysphagiaSignal17910.08.71,447
muscular weaknessSignal1999.38.11,470
urinary tract infectionSignal2146.75.81,030
hospitalisationSignal1756.05.2736
covid-19Signal1745.34.5601
astheniaSignal2633.73.3527
fallSignal2243.63.1418
dyspnoeaSignal3012.82.5361
fatigueSignal4042.82.5466
headache1921.61.447
death1911.21.05
off label use1781.10.91
drug ineffective2160.90.84

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.